Abbott RealTime IDH1
Real-time PCR assay that qualitatively detects IDH1 R132 mutations in blood or bone marrow to help identify patients eligible for IDH1-targeted therapies.
Casandra.ai provides a unified ordering experience so you can request this test directly from the performing lab, without changing your workflow.
Ordering is available where Casandra has an active integration with the performing lab. Labs that offer this test can connect with us to enable digital ordering.
About this test
Abbott RealTime IDH1 is an in vitro real-time PCR assay that qualitatively detects five IDH1 R132 mutations (R132C/H/G/S/L) in DNA from EDTA blood or bone marrow. Run on the Abbott m2000rt System, it reports a positive or negative result to support identification of patients with IDH1-mutated myeloid malignancies who may be candidates for IDH1-targeted therapies.
Where this test fits
| Indication | Biomarker | Biomarker details | Therapy (Select a therapy to open its FDA-approved testing pathway) |
|---|---|---|---|
| Acute Myeloid Leukemia (AML) | IDH1 | R132 mutations (R132C, R132H, R132G, R132S, and R132L) | REZLIDHIA, TIBSOVO |
| Myelodysplastic Syndromes (MDS) | IDH1 | R132 mutations (R132C, R132H, R132G, R132S, and R132L) | TIBSOVO |
IVD Manufacturer
Abbott Molecular is a leader in molecular diagnostics — the analysis of DNA and RNA at the molecular level. Its tests can detect subtle genetic and chromosomal changes that may aid earlier diagnosis, guide therapy selection, and help monitor disease progression.
Order this test
If your organization is connected to Casandra, you can place an electronic order forAbbott RealTime IDH1 directly from your existing workflow.
Casandra connects providers, labs, and sponsored programs so that companion diagnostics can be ordered consistently and documented cleanly, regardless of which system you start from.